O26 Polysaccharides as Key Players in Enteropathogenic <i>E. coli</i> Immune Evasion and Vaccine Development
Enteropathogenic <i>Escherichia coli</i> (EPEC) produce a capsule of polysaccharides identical to those composing the O-antigen polysaccharide of its LPS (lipopolysaccharide) molecules. In light of this, the impact of O26 polysaccharides on the immune evasion mechanisms of capsulated O26...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-03-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/25/5/2878 |
| _version_ | 1797264339093159936 |
|---|---|
| author | Thiago Jordão da Silva Lemos Herbert Guimarães de Sousa Silva José Osvaldo Previato Lucia Mendonça-Previato Elisangela Oliveira de Freitas Angela Silva Barbosa Marcia Regina Franzolin Luis Fernando dos Santos Bruna de Sousa Melo Geovana Ferreira dos Anjos Renata Hiromi Nakagima Gonçalves Marta de Oliveira Domingos |
| author_facet | Thiago Jordão da Silva Lemos Herbert Guimarães de Sousa Silva José Osvaldo Previato Lucia Mendonça-Previato Elisangela Oliveira de Freitas Angela Silva Barbosa Marcia Regina Franzolin Luis Fernando dos Santos Bruna de Sousa Melo Geovana Ferreira dos Anjos Renata Hiromi Nakagima Gonçalves Marta de Oliveira Domingos |
| author_sort | Thiago Jordão da Silva Lemos |
| collection | DOAJ |
| description | Enteropathogenic <i>Escherichia coli</i> (EPEC) produce a capsule of polysaccharides identical to those composing the O-antigen polysaccharide of its LPS (lipopolysaccharide) molecules. In light of this, the impact of O26 polysaccharides on the immune evasion mechanisms of capsulated O26 EPEC compared to non-capsulated enterohemorrhagic <i>Escherichia coli</i> (EHEC) was investigated. Our findings reveal that there was no significant difference between the levels in EPEC and EHEC of rhamnose (2.8:2.5), a molecule considered to be a PAMP (Pathogen Associated Molecular Patterns). However, the levels of glucose (10:1.69), heptose (3.6:0.89) and N-acetylglucosamine (4.5:2.10), were significantly higher in EPEC than EHEC, respectively. It was also observed that the presence of a capsule in EPEC inhibited the deposition of C3b on the bacterial surface and protected the pathogen against lysis by the complement system. In addition, the presence of a capsule also protected EPEC against phagocytosis by macrophages. However, the immune evasion provided by the capsule was overcome in the presence of anti-O26 polysaccharide antibodies, and additionally, these antibodies were able to inhibit O26 EPEC adhesion to human epithelial cells. Finally, the results indicate that O26 polysaccharides can generate an effective humoral immune response, making them promising antigens for the development of a vaccine against capsulated O26 <i>E. coli.</i> |
| first_indexed | 2024-04-25T00:27:19Z |
| format | Article |
| id | doaj.art-08d811dbdb9140c686c2f2f5ce1bff22 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-04-25T00:27:19Z |
| publishDate | 2024-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-08d811dbdb9140c686c2f2f5ce1bff222024-03-12T16:46:40ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672024-03-01255287810.3390/ijms25052878O26 Polysaccharides as Key Players in Enteropathogenic <i>E. coli</i> Immune Evasion and Vaccine DevelopmentThiago Jordão da Silva Lemos0Herbert Guimarães de Sousa Silva1José Osvaldo Previato2Lucia Mendonça-Previato3Elisangela Oliveira de Freitas4Angela Silva Barbosa5Marcia Regina Franzolin6Luis Fernando dos Santos7Bruna de Sousa Melo8Geovana Ferreira dos Anjos9Renata Hiromi Nakagima Gonçalves10Marta de Oliveira Domingos11Laboratório de Bacteriologia, Instituto Butantan, Avenida Vital Brasil, 1500, São Paulo 05503-900, SP, BrazilLaboratório de Bacteriologia, Instituto Butantan, Avenida Vital Brasil, 1500, São Paulo 05503-900, SP, BrazilInstituto de Biofísica Carlos Chagas Filho, UFRJ, Avenida Carlos Chagas Filho, 373, Cidade Universitária, Rio de Janeiro 21941-902, RJ, BrazilInstituto de Biofísica Carlos Chagas Filho, UFRJ, Avenida Carlos Chagas Filho, 373, Cidade Universitária, Rio de Janeiro 21941-902, RJ, BrazilInstituto de Biofísica Carlos Chagas Filho, UFRJ, Avenida Carlos Chagas Filho, 373, Cidade Universitária, Rio de Janeiro 21941-902, RJ, BrazilLaboratório de Bacteriologia, Instituto Butantan, Avenida Vital Brasil, 1500, São Paulo 05503-900, SP, BrazilLaboratório de Bacteriologia, Instituto Butantan, Avenida Vital Brasil, 1500, São Paulo 05503-900, SP, BrazilCentro de Bacteriologia, Núcleo de Doenças Entéricas, Instituto Adolfo Lutz, Avenida Dr. Arnaldo, 355, São Paulo 01246-000, SP, BrazilLaboratório de Bacteriologia, Instituto Butantan, Avenida Vital Brasil, 1500, São Paulo 05503-900, SP, BrazilLaboratório de Bacteriologia, Instituto Butantan, Avenida Vital Brasil, 1500, São Paulo 05503-900, SP, BrazilLaboratório de Bacteriologia, Instituto Butantan, Avenida Vital Brasil, 1500, São Paulo 05503-900, SP, BrazilLaboratório de Bacteriologia, Instituto Butantan, Avenida Vital Brasil, 1500, São Paulo 05503-900, SP, BrazilEnteropathogenic <i>Escherichia coli</i> (EPEC) produce a capsule of polysaccharides identical to those composing the O-antigen polysaccharide of its LPS (lipopolysaccharide) molecules. In light of this, the impact of O26 polysaccharides on the immune evasion mechanisms of capsulated O26 EPEC compared to non-capsulated enterohemorrhagic <i>Escherichia coli</i> (EHEC) was investigated. Our findings reveal that there was no significant difference between the levels in EPEC and EHEC of rhamnose (2.8:2.5), a molecule considered to be a PAMP (Pathogen Associated Molecular Patterns). However, the levels of glucose (10:1.69), heptose (3.6:0.89) and N-acetylglucosamine (4.5:2.10), were significantly higher in EPEC than EHEC, respectively. It was also observed that the presence of a capsule in EPEC inhibited the deposition of C3b on the bacterial surface and protected the pathogen against lysis by the complement system. In addition, the presence of a capsule also protected EPEC against phagocytosis by macrophages. However, the immune evasion provided by the capsule was overcome in the presence of anti-O26 polysaccharide antibodies, and additionally, these antibodies were able to inhibit O26 EPEC adhesion to human epithelial cells. Finally, the results indicate that O26 polysaccharides can generate an effective humoral immune response, making them promising antigens for the development of a vaccine against capsulated O26 <i>E. coli.</i>https://www.mdpi.com/1422-0067/25/5/2878<i>E. coli</i> O26vaccineenteropathogenic <i>E. coli</i>EPECenterohemorrhagic <i>E. coli</i>EHEC |
| spellingShingle | Thiago Jordão da Silva Lemos Herbert Guimarães de Sousa Silva José Osvaldo Previato Lucia Mendonça-Previato Elisangela Oliveira de Freitas Angela Silva Barbosa Marcia Regina Franzolin Luis Fernando dos Santos Bruna de Sousa Melo Geovana Ferreira dos Anjos Renata Hiromi Nakagima Gonçalves Marta de Oliveira Domingos O26 Polysaccharides as Key Players in Enteropathogenic <i>E. coli</i> Immune Evasion and Vaccine Development International Journal of Molecular Sciences <i>E. coli</i> O26 vaccine enteropathogenic <i>E. coli</i> EPEC enterohemorrhagic <i>E. coli</i> EHEC |
| title | O26 Polysaccharides as Key Players in Enteropathogenic <i>E. coli</i> Immune Evasion and Vaccine Development |
| title_full | O26 Polysaccharides as Key Players in Enteropathogenic <i>E. coli</i> Immune Evasion and Vaccine Development |
| title_fullStr | O26 Polysaccharides as Key Players in Enteropathogenic <i>E. coli</i> Immune Evasion and Vaccine Development |
| title_full_unstemmed | O26 Polysaccharides as Key Players in Enteropathogenic <i>E. coli</i> Immune Evasion and Vaccine Development |
| title_short | O26 Polysaccharides as Key Players in Enteropathogenic <i>E. coli</i> Immune Evasion and Vaccine Development |
| title_sort | o26 polysaccharides as key players in enteropathogenic i e coli i immune evasion and vaccine development |
| topic | <i>E. coli</i> O26 vaccine enteropathogenic <i>E. coli</i> EPEC enterohemorrhagic <i>E. coli</i> EHEC |
| url | https://www.mdpi.com/1422-0067/25/5/2878 |
| work_keys_str_mv | AT thiagojordaodasilvalemos o26polysaccharidesaskeyplayersinenteropathogeniciecoliiimmuneevasionandvaccinedevelopment AT herbertguimaraesdesousasilva o26polysaccharidesaskeyplayersinenteropathogeniciecoliiimmuneevasionandvaccinedevelopment AT joseosvaldopreviato o26polysaccharidesaskeyplayersinenteropathogeniciecoliiimmuneevasionandvaccinedevelopment AT luciamendoncapreviato o26polysaccharidesaskeyplayersinenteropathogeniciecoliiimmuneevasionandvaccinedevelopment AT elisangelaoliveiradefreitas o26polysaccharidesaskeyplayersinenteropathogeniciecoliiimmuneevasionandvaccinedevelopment AT angelasilvabarbosa o26polysaccharidesaskeyplayersinenteropathogeniciecoliiimmuneevasionandvaccinedevelopment AT marciareginafranzolin o26polysaccharidesaskeyplayersinenteropathogeniciecoliiimmuneevasionandvaccinedevelopment AT luisfernandodossantos o26polysaccharidesaskeyplayersinenteropathogeniciecoliiimmuneevasionandvaccinedevelopment AT brunadesousamelo o26polysaccharidesaskeyplayersinenteropathogeniciecoliiimmuneevasionandvaccinedevelopment AT geovanaferreiradosanjos o26polysaccharidesaskeyplayersinenteropathogeniciecoliiimmuneevasionandvaccinedevelopment AT renatahirominakagimagoncalves o26polysaccharidesaskeyplayersinenteropathogeniciecoliiimmuneevasionandvaccinedevelopment AT martadeoliveiradomingos o26polysaccharidesaskeyplayersinenteropathogeniciecoliiimmuneevasionandvaccinedevelopment |